Aberrant activation of FTO sensitizes renal clear cell carcinoma to BRD9 inhibitors (Zhang et al., 2021[336]), and FTO inhibits clear cell renal cell carcinoma through the PGC-1α signaling axis (Zhuang et al., 2019[378]). This evidence concerns the gene PPARGC1A and clear cell renal carcinoma.